With an estimated 33.2 million people in the world infected with the virus, human immunodeficiency virus (HIV) is a major medical problem.
The purpose of this study is to evaluate the safety of a new medication (GSK1349572) in HIV infected individuals who have never taken antiretroviral medications before. This study is also comparing the efficacy of GSK1349572 + epzicom to Atripla which is currently one of the medications used for HIV therapy.
Who may be Eligible
You may be eligible if you:
Are an HIV infected individual who is 18 years old or older
Have never taken HIV medications.
Have a viral load >1000 copies/mL
You are not pregnant or breastfeeding or planning on becoming pregnant during the term of the trial (96 weeks).
Not have a positive HLA-B*5701 which is verified by your doctor
Have no active AIDS defining illness at your first study visit.
Have not received an HIV-1 vaccine in the past 90 days
Do not meet criteria of exclusion based on your routine lab results
Do not have a history of cancer in the past 5 years
Will not be treated for hepatitis C during the study term.
Have not received an experimental medication within 28 days